⁉️Quick question for clinicians We're exploring insulin management in type 2 diabetes. Is the following a gap in clinical practice? Patients do not consistently receive the education and support needed to sustain long-term insulin use.

📣Calling all HCPs We're exploring insulin management in type 2 diabetes. Is the following a gap in clinical practice? Selecting the most appropriate insulin strategy can be challenging when balancing efficacy, safety, and patient preferences.

📊Clinician insights wanted We're exploring insulin management in type 2 diabetes. Is the following a gap in clinical practice? Clinicians lack confidence in discussing the role of newer once-weekly insulin therapies with patients.

👋HCPs, we want to hear from you We're exploring insulin management in type 2 diabetes. Is the following a gap in clinical practice? Treatment escalation to insulin therapy is often delayed even when patients remain above glycemic targets.

🤝 Healthcare professionals: we'd value your perspective. Is this a challenge in practice? Coordinating multidisciplinary care and individualized management for patients with progressing mycosis fungoides and Sézary syndrome.

📈 Calling all healthcare professionals. We'd value your perspective. Is this a challenge in clinical practice? Determining when disease progression warrants reassessment, referral, or consideration of systemic therapy in mycosis fungoides and Sézary syndrome can be complex.

🔍 Calling all healthcare professionals. We'd value your perspective. Is this a challenge in clinical practice? Recognizing and diagnosing mycosis fungoides and Sézary syndrome can be difficult because presentations may resemble more common skin conditions.

🩺 HCPs, we'd value your perspective We're exploring preparedness for emerging therapies. Is the following a gap in clinical practice? Applying new evidence and targeted therapies in Juvenile Myasthenia Gravis (JMG), including understanding mechanisms and patient selection.

Welcome to the next instalment in our accredited Epithelioid Sarcoma Quick Bits social learning series. Watch this short reel with Dr Seth Pollack on the role of INI1 loss in diagnosing epithelioid sarcoma. Review evidence-based diagnostic considerations, including: 🔬 INI1 loss as a key clue in suspected ES 🧫 Morphology and broad immunohistochemistry in the differential diagnosis 🧬 When SMARCB1 FISH or NGS may support confirmation 🤝 Integrating pathology, imaging, and multidisciplinary review Please read the CE information and disclosures here before participating in this activity: app.medall.org/articles/es-q… This program is supported by an independent educational grant from Ipsen. This education program is available to healthcare professionals globally. 👉🏽 Get the full series in the link below app.medall.org/articles/es-q…

This is part of our Epithelioid Sarcoma Quick Bits social learning series. Get the full series in the link below. Watch this short reel with Dr Hannah Abrams on treatment sequencing beyond first-line therapy in epithelioid sarcoma. Review evidence-based considerations for later-line ES management, including: 🔄 Sequencing options after progression on first-line therapy 💊 Anthracycline-, gemcitabine-, and pazopanib-based approaches 📊 Real-world response and progression-free survival data 🤝 Individualizing treatment based on subtype, tolerability, quality of life, and patient goals 🏥 Referral to sarcoma-specialized centers and clinical trial consideration Please read the CE information and disclosures here before participating in this activity: app.medall.org/articles/es-q… This program is supported by an independent educational grant from Ipsen. This education program is available to healthcare professionals globally. 👉🏽 Get the full series in the link below app.medall.org/articles/es-q…

Check out the next part of our Epithelioid Sarcoma Quick Bits social learning series. Get the full series in the link below. Watch this short reel with Dr Hannah Abrams on emerging treatment directions in epithelioid sarcoma. Review evidence-based considerations on evolving approaches, including: 🧬 SMARCB1-deficient biology and rationale for targeted strategies 💊 Anti-angiogenic TKI-based combinations in soft-tissue sarcoma 🛡️ Immunotherapy combinations, including checkpoint blockade approaches 📊 Emerging clinical data and investigational strategies relevant to ES 🏥 Clinical trial consideration in this ultra-rare sarcoma Please read the CE information and disclosures here before participating in this activity: app.medall.org/articles/es-q… This program is supported by an independent educational grant from Ipsen. This education program is available to healthcare professionals globally. 👉🏽 Get the full series in the link below app.medall.org/articles/es-q…

This is part of our Epithelioid Sarcoma Quick Bits social learning series. Get the full series in the link below. Watch this short reel with Dr Hannah Abrams on first-line systemic therapy considerations in advanced epithelioid sarcoma. Review evidence-based treatment considerations, including: 💊 Anthracycline-based chemotherapy as a preferred first-line systemic approach 🧬 Classic vs proximal-type ES and implications for treatment discussions 📊 Real-world data on doxorubicin- and gemcitabine-based regimens 🤝 Individualizing therapy based on disease extent, comorbidities, performance status, and patient goals Please read the CE information and disclosures here before participating in this activity: app.medall.org/articles/es-q… This program is supported by an independent educational grant from Ipsen. This education program is available to healthcare professionals globally. 👉🏽 Get the full series in the link below

Welcome to our new, accredited social learning series on Epithelioid Sarcoma: Quick Bits. Watch this short reel with Dr Seth Pollack on early recognition of epithelioid sarcoma. Review evidence-based warning signs that may prompt further evaluation, including: 🔎 Slow-growing, painless soft-tissue nodules 📏 Size, depth, pain, firmness, or progressive enlargement 🩻 MRI features that may raise suspicion 🤝 When to escalate to biopsy and multidisciplinary review Please read the CE information and disclosures here before participating in this activity: app.medall.org/articles/es-q… This program is supported by an independent educational grant from Ipsen. This education program is available to healthcare professionals globally. 👉🏽 Get the full series in the link below

👋HCPs, we'd value your perspective We're exploring understanding of IgAN pathogenesis. Is the following a gap in clinical practice? Understanding the role of B-cell dysregulation and upstream immune mechanisms in the progression of IgAN:

👋HCPs we’d love to hear from you We’re exploring alcohol-use disorder (AUD) management Is the following a gap in clinical practice? HCPs face challenges in developing multidisciplinary chronic care pathways for AUD that combine nonpharmacologic and pharmacologic approaches.

📊HCP perspectives wanted We’re exploring alcohol-use disorder (AUD) management Is the following a gap in clinical practice? HCPs face challenges in setting guideline-based treatment goals centered on patient-centric harm-reduction

⁉️Quick question for HCPs We’re exploring alcohol-use disorder (AUD) management Is the following a gap in clinical practice? HCPs face challenges in selecting targeted pharmacotherapeutics that address the neurobiology of AUD